ClinicaliQ Trial Snapshot
- A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer — Active Not Recruiting • Phase III • Oncology • NCT04739761.
- T-DXd improves outcomes in HER2-positive advanced breast cancer patients previously treated with anti-HER2 drugs, including those with brain metastases.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is open-label, multicenter, international study, assessing the efficacy and safety of Trastuzumab deruxtecan (T-DXd) in participants with or without brain metastasis (BMs), with previously-treated advanced/metastatic HER2-positive breast cancer whose disease has progressed on prior anti-HER2-based regimens and who received no more than 2 lines/regimens of therapy in the metastatic setting (excluding tucatinib). Conditions: Breast Cancer Interventions: Trastuzumab Deruxtecan Lead Sponsor: AstraZeneca Planned Enrollment: 506 participants